Table 3.

Laboratory findings in patients with multiple myeloma and COVID-19

	All patients			With combined adverse outcome			Without combined adverse outcome
	n = 100			n = 29			n = 71
	Median	Range	n	Median	Range	n	Median	Range	n	Reference range	P
ANC	3.2	0.4–17.5	82	4.0	0.4–17.2	26	2.5	0.4–17.5	56	1.5–7.5 (×109/L)	0.025
ALC	0.6	0.1–1.8	82	0.6	0.1–1.2	26	0.7	0.1–1.8	56	0.9–3.2 (×109/L)	0.21
Platelets	152	6–507	82	119	6–350	26	164.5	19–507	56	160–400 (×109/L)	0.037
C-reactive protein	34	2.7–293	65	37	5.5–293	25	25.5	2.7–259	40	<0.50 (mg/dL)	0.25
Ferritin	658	2–40,000	64	2,015	42–40,000	25	476	2–7,174	39	22–415 (ng/mL)	0.001
D-dimer	1.3	0.2–83	59	3.0	0.3–83	24	0.9	0.2–5.5	35	<0.5 (mcg/mL FEU)	0.001
IL-6	71	6–3,238	50	102	7.3–3,238	21	64.5	6.0–532	29	<5.0 (pg/dL)	0.14

Note: Adverse combined endpoint = ICU admission, mechanical ventilation, or death. Wilcoxon rank test was used to compare laboratory values for patients who had the combined adverse outcome versus patients without the adverse outcome.

Abbreviations: ANC, absolute neutrophil count; ALC, absolute lymphocyte count; IL-6, interleukin 6.